2,5,8,11-Tetraoxahexadecan-16-oic acid | 405518-51-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,5,8,11-Tetraoxahexadecan-16-oic acid
• 英文别名: 5-[2-[2-(2-Methoxyethoxy)ethoxy]ethoxy]pentanoic acid
• CAS: 405518-51-6
• 化学式: C₁₂H₂₄O₆
• mdl: MFCD26498239
• 分子量: 264.319
• InChiKey: ZROUBWHDQKOJPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  18
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.916
• 拓扑面积：
  74.2
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Novel alkanoic acid derivaties
  申请人：——

  公开号：US20040067202A1

  公开（公告）日：2004-04-08

  There are provided according to the invention compounds of the formula (I) or a salt or solvate thereof, wherein: n represents an integer 1 to 6; N represents an integer 1 to 15; R 1 represents (CO) x C 1-9 alkyl or (CO) x C 1-9 fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms wherein x represents 0 or 1; and R 2 and R 3 independently represent C 1-3 alkyl or hydrogen. There are also provided pharmaceutical aerosol formulations employing said compounds as suspension stabilising agents.

  本发明提供了化合物(I)或其盐或溶剂，其中：n表示1至6的整数；N表示1至15的整数；R1表示(CO)xC1-9烷基或(CO)xC1-9氟烷基，其中氟烷基含有至少1个氟原子，但不超过3个连续的全氟碳原子，其中x表示0或1；R2和R3独立地表示C1-3烷基或氢。本发明还提供了以所述化合物作为悬浮稳定剂的制药气雾剂配方。
• NOVEL ALKANOIC ACID DERIVATIVES
  申请人：GLAXO GROUP LIMITED

  公开号：EP1318973A2

  公开（公告）日：2003-06-18
• US7217409B2
  申请人：——

  公开号：US7217409B2

  公开（公告）日：2007-05-15
• [EN] NOVEL ALKANOIC ACID DERIVATIVES<br/>[FR] NOUVEAUX DERIVES D'ACIDE ALCANOIQUE
  申请人：GLAXO GROUP LTD

  公开号：WO2002024623A2

  公开（公告）日：2002-03-28

  There are provided according to the invention compounds of the formula (I) or a salt or solvate thereof, wherein: n represents an integer 1 to 6; N represents an integer 1 to 15; R1 represents (CO)¿x?C1-9alkyl or (CO)xC1-9fluoroalkyl, which fluoroalkyl moiety contains at least 1 fluorine atom and not more than 3 consecutive perfluorocarbon atoms wherein x represents 0 or 1; and R?2 and R3¿ independently represent C¿1-3?alkyl or hydrogen. There are also provided pharmaceutical aerosol formulations employing said compounds as suspension stabilising agents.